131 related articles for article (PubMed ID: 37934084)
1. Evaluation of tumor-infiltrating lymphocytes and mammographic density as predictors of response to neoadjuvant systemic therapy in breast cancer.
Landén AH; Chin K; Kovács A; Holmberg E; Molnar E; Stenmark Tullberg A; Wärnberg F; Karlsson P
Acta Oncol; 2023 Dec; 62(12):1862-1872. PubMed ID: 37934084
[TBL] [Abstract][Full Text] [Related]
2. Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer.
Skarping I; Förnvik D; Sartor H; Heide-Jørgensen U; Zackrisson S; Borgquist S
BMC Cancer; 2019 Dec; 19(1):1272. PubMed ID: 31888552
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
4. Mammographic density to predict response to neoadjuvant systemic breast cancer therapy.
Di Cosimo S; Depretto C; Miceli R; Baili P; Ljevar S; Sant M; Cappelletti V; Folli S; Gennaro M; De Braud FG; Bianchi G; Vingiani A; Pruneri G; Marchianò A; La Rocca E; De Santis MC; Scaperrotta GP
J Cancer Res Clin Oncol; 2022 Apr; 148(4):775-781. PubMed ID: 35037102
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
7. Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer.
Abe N; Matsumoto H; Takamatsu R; Tamaki K; Takigami N; Uehara K; Kamada Y; Tamaki N; Motonari T; Unesoko M; Nakada N; Zaha H; Yoshimi N
Virchows Arch; 2020 May; 476(5):701-709. PubMed ID: 31873876
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
[TBL] [Abstract][Full Text] [Related]
9. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.
Miskad UA; Rifai RA; Masadah R; Nelwan B; Ahmad D; Cangara H; Prihantono P; Zainuddin AA; Rahawarin H
Breast Dis; 2021; 40(S1):S9-S14. PubMed ID: 34092582
[TBL] [Abstract][Full Text] [Related]
10. Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden.
Skarping I; Förnvik D; Heide-Jørgensen U; Sartor H; Hall P; Zackrisson S; Borgquist S
Breast; 2020 Oct; 53():33-41. PubMed ID: 32563178
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis.
Yokotani T; Ikeda N; Hirao T; Tanaka Y; Morita K; Fujii T; Ohbayashi C; Nakamura T; Kobayashi T; Sho M
Surg Today; 2021 Apr; 51(4):595-604. PubMed ID: 33052489
[TBL] [Abstract][Full Text] [Related]
12. The association between breast density and breast cancer pathological response to neoadjuvant chemotherapy.
Cullinane C; Brien AO; Shrestha A; Hanlon EO; Walshe J; Geraghty J; Evoy D; McCartan D; McDermott E; Prichard R
Breast Cancer Res Treat; 2022 Jul; 194(2):385-392. PubMed ID: 35606616
[TBL] [Abstract][Full Text] [Related]
13. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
14. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
15. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
16. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy.
Agarwal G; Vishvak Chanthar KMM; Katiyar S; Kumari N; Krishnani N; Sabaretnam M; Chand G; Mishra A; Lal P
World J Surg; 2023 May; 47(5):1238-1246. PubMed ID: 36735048
[TBL] [Abstract][Full Text] [Related]
17. The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer.
Kimura Y; Masumoto N; Kanou A; Fukui K; Sasada S; Emi A; Kadoya T; Arihiro K; Okada M
Surg Oncol; 2022 May; 41():101725. PubMed ID: 35189516
[TBL] [Abstract][Full Text] [Related]
18. Tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in relation to pathological complete remission to neoadjuvant therapy and prognosis in triple negative breast cancer.
Zhao M; Xing H; He J; Wang X; Liu Y
Pathol Res Pract; 2023 Aug; 248():154687. PubMed ID: 37478522
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
20. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
Mao Y; Qu Q; Zhang Y; Liu J; Chen X; Shen K
PLoS One; 2014; 9(12):e115103. PubMed ID: 25501357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
